~~<i id='F9889AEE4F'><strike id='F9889AEE4F'><tt id='F9889AEE4F'><pre id='F9889AEE4F'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：Wikipedia 2025-09-29 03:01:16 Page View：47977

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novo Nordisk to expand supply of Wegovy for U.S. patients
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

The lessons of Aduhelm, an Alzheimer's drug that was not to be

StevenSenn/APAduhelm,apioneeringtreatmentforAlzheimer’sdiseasethatcollapsedundercorporatemistakesand

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Quicker fix for pulse oximeters urged during FDA public meeting

AdobeTheFoodandDrugAdministrationshouldmovemorequicklytoensurepulseoximeters—theubiquitousdevicesuse